Dr Martens mulls IPO, as other firms also plan UK listing
Investors are piling into UK equities, helped by a long-awaited Brexit deal and global growth optimism
London — Dr Martens is considering an initial public offering (IPO) on the London Stock Exchange, as owner Permira Holdings seeks to sell a stake in the iconic British bootmaker amid rallying stock markets.
The company does not plan to raise any money in the IPO, according to a statement released on Monday.
Permira began working with advisers in mid-2019 on ways to offload Dr Martens and attracted interest from suitors including rival private equity firm Carlyle Group, Bloomberg News reported at the time. Those discussions didn’t result in an agreement and Permira is said to have revived plans to exit its investment last year.
Strong equity markets are making IPOs an attractive exit option once again, with the benchmark FTSE 100 Index posting its best start to a year on record. Investors are piling into UK equities, helped by a long-awaited Brexit deal and global growth optimism. Dr Martens is the third company to lay out plans for a London listing in two weeks.
Since paying €380m for the bootmaker in 2014, Permira has increased the brand’s global presence, opening new stores and expanding its e-commerce offering.
At least 25% of Dr Martens’ share capital will be available for trading upon listing, the company said on Monday, adding that it expects to be eligible for inclusion in the FTSE UK indices. A further 15% will be made available in an over-allotment option.
Dr Martens posted an 18% year-on-year increase in group revenue to £318.2m in the six months ended September 30, while earnings before interest, taxes, depreciation and amortisation rose 30% to £86.3m in that period, according to the statement.
Goldman Sachs and Morgan Stanley are joint global coordinators, while Barclays, BofA Securities, HSBC and Royal Bank of Canada will be joint bookrunners in the event the offer proceeds. Lazard & Co is the company’s financial adviser.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.